Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027
May 08, 2023 at 06:30 am EDT
Share
Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million.
For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million.
For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million.
For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million.
For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
ENZO BIOCHEM, INC. 
